Opinion|Videos|September 17, 2024
Innovations and Future Directions in Higher Risk MDS Treatments
Medical experts discuss innovations and future directions in treatments for higher-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key challenges in developing effective therapies for patients with TP53-mutated higher-risk myelodysplastic syndromes (MDS), and what strategies are being explored to address these challenges?
- What innovations in the pipeline for higher-risk MDS treatments are you most excited about? What role do you think novel targeted therapies and/or combination therapy will have in future MDS treatment paradigms?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Physical Function Views Differ Between Older AML Patients, Clinicians
3
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
4
Better Cardiovascular Health Tied to Lower Overactive Bladder Risk
5